Medicare now covers the v go under part d, and that disposable patch like devices. New wearable, patchlike device steadily delivers insulin for. You can also deliver boluses with the push of a button. Another great outcome of all of our clinical data was having the american diabetes association, or the ada, include the use of a disposable patchlike device, such as. American diabetes association includes disposable patch. I n the summer of 2012, valeritas launched its flagship product, the vgo wearable insulin delivery device. Contacts tara charvat vice president, marketing valeritas.
Valeritas enable study demonstrates significant clinical. Other adverse reactions associated with v go use include skin irritation from the adhesive pad or infections at the infusion site. Humalog and novorapid have been tested by valeritas, inc. Valeritas ceo appears on fox business networks top morning show. Medicare now covers the vgo under part d, and that disposable patchlike devices. Apr 15, 20 if you have any questions regarding the operation of the v go or ez fill, speak to a valeritas customer care representative 247 at 18668811209. We recently reported our third consecutive quarter of record revenue which is a direct result of v go gaining momentum among patients with type 2 diabetes.
V go device received approval in 2010 from the food and drug administration fda. V go disposable insulin delivery device may result in hypoglycaemia. Vgo an affordable, oncedaily, wearable insulin delivery device that you wear like a patch. V go is a small, discreet and easytouse disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. Insulin delivery devices market size is estimated to grow. Vgo disposable insulin delivery device prior approval. Vgo insulin delivery system versus multiple daily insulin. Valeritas presents positive hpatch apomorphine study. About the v go disposable insulin delivery device the v go is the first simple, fully disposable device designed and cleared for the delivery of basalbolus insulin therapy for adults with diabetes. Edited transcript of vlrx earnings conference call or. Mar 01, 2011 the vgo and thereby have increased healthcare professional and patient insulin options available for use with the vgo disposable insulin delivery device said valeritas ceo kristine peterson. Diabetes product news from adas scientific sessions 2019. Medicine only works if patients take it, says john.
The v go device is filled with insulin by the patient and adheres to the skin via a patch. Imperiums design is in many ways similar to the vgo patch pump by valeritas and the cequr paq device. American diabetes association includes disposable patch like device, such as vgo from valeritas, in the ada standards of medical care in diabetes 2019. The following conditions may occur during insulin therapy with v go. V go is discreet, simpletouse, costeffective, clinically proven, and the only disposable, daily insulin delivery option, he added. Jan 05, 2018 through an oemtype business model, imperium will not be marketed and sold as its own brand, but rather by the insulin companies themselves similar to the way they license insulin pen devices and sell them as their own products. Imperiums design is in many ways similar to the v go patch pump by valeritas and the cequr paq device. American diabetes association includes disposable patchlike. The v go is a single use 24 hour disposable device. V go is designed to simplify basalbolus insulin therapy and helps make blood glucose control possible for adults. Anywhere between 2040 units of basal insulin can be programed to be given, it works like the background insulin the pancreas is meant to give off in a nondiabetic person.
Valeritas ceo appears on fox business networks top morning. Whereas traditional pumps consist of an insulin reservoir a device. About the v go disposable insulin delivery device the v go is the first simple, fully disposable device for the delivery of basalbolus insulin therapy for adults with diabetes. Vlrx has the support of the american diabetes association with regards to its disposable insulin delivery patch, which isnt a bad start. The v go disposable insulin delivery device, designed for the simple delivery of basalbolus insulin therapy via a preset basal rate and ondemand bolus dosing around mealtimes, is the first use of the h patch. While the process of bringing the v go to market began in 1999, fda approval was obtained in december 2010 and the v go was launched regionally starting in may of 2012.
Valeritas ceo appears on fox business networks top. The patch pump has a set basal range and a button for boluses. Valeritas medical technologies portfolio is headlined by the hpatchtm technology. Like a traditional insulin pump, vgo is a convenient alternative to needles and syringes for injecting insulin multiple times throughout the daywith one big difference. It is approved on the basis that the device is substantially. The original hpatch product received food and drug administration fda 510k premarket approval in 2005. The v go is a newly developed insulin delivery system manufactured by valeritas out of bridgewater, nj. Vgo disposable insulin delivery device full indication statement. Insulin delivery with v go was associated with a greater reduction in a1c and required less insulin than patients using an insulin pen. Study limitations include retrospective design and patientreported outcomes.
V go is a simple, affordable, and fully disposable device and works with no electronics, batteries, infusion sets, or programming. Bridgewater, new jersey, november 3, 2015 valeritas inc. Vgo is a prescriptiononly insulin delivery system for people with type 2 diabetes who require insulin in order to control their blood glucose sugar. Bridgewater, new jersey, february 16, 2016 valeritas inc. Sep 15, 2011 this upround further validates the value of valeritas and the v go. V go disposable insulin delivery device prior approval october 2016 overview continuous insulin delivery may be required for type 1 diabetics or those type 2 diabetics who are insulin dependent. Aug 25, 2015 imperiums design is in many ways similar to the v go patch pump by valeritas and the cequr paq device.
V go is a 24hour small, disposable mechanical device that, according to its manufacturer, valeritas, inc. Similar to the v go from valeritas, the onetouch via is an entirely mechanical, tubeless, and disposable patch pump. Letter from the fda to valeritas regarding status of v go device disposable insulin deliver device. Dec 09, 2010 valeritas plans to commercialize the v go in the united states in 2011. Steady rate of insulin 247 basal ondemand dosing at mealtimes and snacks bolus apply one vgo patch pump, once a day. Oncedaily insulin delivery device for type 2 diabetes vgo. The first use of the hpatchtm technology will be the vgotm disposable insulin delivery device for the simple delivery of basalbolus therapy via a preset basal rate and ondemand bolus dosing around mealtimes. This upround further validates the value of valeritas and the vgo. May 28, 2019 american diabetes association includes disposable patchlike device, such as vgo from valeritas, in the ada standards of medical care in diabetes 2019. Vlrx has the support of the american diabetes association with regards to its disposable insulin delivery patch, which isnt a. V go helps you because it delivers insulin much like your body is supposed to. Valeritas receives fda 510k clearance todays medical. Valeritas hpatch the vgois an insulin delivery system for diabetics currently only type 2 diabetics it is a small, lightweight disposable device 2. Valeritas, vgo and our logo are some of our trademarks used in this prospectus.
It also provides discreet ondemand bolus dosing at mealtimes. Medicine only works if patients take it, says john timberlake, ceo and president of valeritas, a diabetes management device manufacturer. Valeritas holdings vlrx ceo john timberlake on q2 2019. Jan 05, 2018 traditional insulin pumps present their own challenges, as most have long tubing and complicated electronic interfaces that are not userfriendly. Vlrx, a medical technology company and maker of vgo wearable insulin delivery device, today announced the inclusion by the american diabetes association ada of the use of a disposable patch like device for insulin delivery in the new diabetes technology chapter of adas annual standards of. A needle delivers the insulin and the device is removed every twentyfour hours. Understanding that people with type 2 diabetes may not require as intensive insulin therapy as those with type 1, valeritas created the disposable vgo. The pump has no electronics, batteries, or programming. The device had been disposed of at the hospital and could not be investigated. Valeritas flagship product, vgo wearable insulin delivery device, is a simple, affordable, allinone basalbolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots.
Learn how vgo can simplify life with type 2 diabetes. External insulin pumps deliver insulin through a catheter and needle into fatty skin tissue. Vgo administers a continuous preset basal rate of insulin over. The valeritas medical technologies portfolio is headlined by the hpatchtm technology.
If youre looking to ditch the multiple daily injections but dont need the advanced features pumps provide, check out valeritass vgo. The v go user assigns indemnity to amsl diabetes from and against all claims of whatsoever nature to the maximum extent permitted by law relating whether directly or indirectly to the v go system. Valeritas device created for people with type 2 diabetesincrements of 0. Valeritas flagship product, vgo disposable insulin delivery device, is a simple, wearable, basalbolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. Another great outcome of all of our clinical data was having the american diabetes association or the ada include the use of the disposable patchlike device, such as vgo for instant delivery and. New wearable, patchlike device steadily delivers insulin. Valeritas promotes matthew nguyen to chief commercial officer. The valeritas vgo works as a basal bolus insulin delivery system which a set amount of a basal insulin is delivered to the wearer throughout the day. This springdriven patch pump is worn on the skin to provide a preset basal rate and ondemand bolus dosing. The pt did not returned a signed release of info from to get addl data from the hospital. Vgo is a 24hour small, disposable mechanical device that, according to its manufacturer, valeritas, inc. Vgo is a small, disposable, easytouse insulin delivery device that is worn like a patch for 24 hours. Disposable insulin delivery device molina healthcare. V go also enables you to give yourself a dose of insulin at mealtimes bolus.
Vlrx, a medical technology company and maker of the vgo wearable insulin delivery device, which uses its proprietary h patch technology, announced positive data. The product was designed around the needs of the patient with. Valeritas vgo the vgo is a simpletouse, oncedaily, disposable insulin delivery device. Vgo disposable insulin delivery device is indicated for continuous subcutaneous infusion of 20 units of insulin in one 24hour time period 0. If you follow the v go instructions for patient use. Patch pump if youd like to avoid multiple daily injections but dont need the bells and whistles of an insulin pump, consider the lowertech vgo. About the vgo disposable insulin delivery device the vgo is the first simple, fully disposable device for the delivery of basalbolus. The device, created specifically for people with type 2 diabetes, sticks to the body and automatically delivers basal insulin. It helps you manage type 2 diabetes by delivering a steady rate of insulin 24 hours a day basal. While it appears largely aimed at the type 2 audience, unilife does seem to be pitching this. We designed our first commercialized product, the v go disposable insulin delivery device, or v go, to help patients with type 2 diabetes who require insulin to achieve and maintain their target blood glucose goals.
334 437 100 943 1486 26 692 217 487 648 1238 1038 721 1008 1264 408 873 920 809 968 149 491 226 954 787 1047 786 983 735 1524 1229 1594 1446 627 880 1337 155 251 943 1136 918 878 231